Apharm

Ethica Corporate Finance advised Apharm in the sale of a majority stake to Nutrilinea

Ethica Corporate Finance advised the shareholders of Apharm, a leading player in the market of food supplements and medical devices, in the sale of a majority stake to Nutrilinea.

This partnership will contribute to creating a leading European player in the production and development of nutraceuticals, combining Nutrilinea’s high quality manufacturing standards and operational flexibility with Apharm’s ability to develop new products.

Over the years, Apharm has established itself as a leader in the market for food supplements and medical devices, relying on a solid IP with more than ten families of patents, especially in the areas of gastrointestinal and orthopaedic therapy, and circa 40 trademarks registered worldwide.

Angelo and Paolo Pizzoni, Apharm founders, will maintain a 30% stake in the company and will continue to operate with executive remit in the context of strategic development and product innovation and sales.

News